AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates
AbbVie is making its largest post-Allergan acquisition in a $10.9 billion move for immunology biotech Apogee Therapeutics. Apogee's long-acting IL-13 drug, call...
AbbVie is making its largest post-Allergan acquisition in a $10.9 billion move for immunology biotech Apogee Therapeutics. Apogee's long-acting IL-13 drug, called zumilokibart, is slated to enter Phase 3 for eczema later this year. The ...